<DOC>
	<DOC>NCT02053454</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics (PK) of patisiran (ALN-TTR02) in Japanese subjects</brief_summary>
	<brief_title>A Study of the Safety, Tolerability and Pharmacokinetics of ALN-TTR02 in Japanese Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Amyloidosis</mesh_term>
	<criteria>Healthy Japanese adult males and females aged 20 to 65 years, inclusive (The subject was born in Japan and has lived outside of Japan for &lt;10 years, and subject's biological parents and grandparents are fully Japanese and were born in Japan); Subjects who are healthy as determined by clinical assessments; Females subjects must be of nonchildbearing potential; Males with partners of childbearing potential, must agree to use appropriate contraception. Subjects with a history of serious mental illness; Subjects who have a clinically relevant medical or surgical history; Subjects with a positive screen for alcohol or drugs of abuse; Subjects with safety laboratory test results deemed clinically significant; Subjects with known hepatitis B surface antigen (HBsAg), hepatitis B virus (HBV), hepatitis C virus (HCV) or human immunodeficiency virus (HIV) infection; Subjects who have received an investigational agent within the 3 months prior to study entry.</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>RNAi therapeutic</keyword>
</DOC>